Radiomics Features of Multiparametric MRI As Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma
Overview
Authors
Affiliations
To identify MRI-based radiomics as prognostic factors in patients with advanced nasopharyngeal carcinoma (NPC). One-hundred and eighteen patients (training cohort: = 88; validation cohort: = 30) with advanced NPC were enrolled. A total of 970 radiomics features were extracted from T2-weighted (T2-w) and contrast-enhanced T1-weighted (CET1-w) MRI. Least absolute shrinkage and selection operator (LASSO) regression was applied to select features for progression-free survival (PFS) nomograms. Nomogram discrimination and calibration were evaluated. Associations between radiomics features and clinical data were investigated using heatmaps. The radiomics signatures were significantly associated with PFS. A radiomics signature derived from joint CET1-w and T2-w images showed better prognostic performance than signatures derived from CET1-w or T2-w images alone. One radiomics nomogram combined a radiomics signature from joint CET1-w and T2-w images with the TNM staging system. This nomogram showed a significant improvement over the TNM staging system in terms of evaluating PFS in the training cohort (C-index, 0.761 vs. 0.514; < 2.68 × 10). Another radiomics nomogram integrated the radiomics signature with all clinical data, and thereby outperformed a nomogram based on clinical data alone (C-index, 0.776 vs. 0.649; < 1.60 × 10). Calibration curves showed good agreement. Findings were confirmed in the validation cohort. Heatmaps revealed associations between radiomics features and tumor stages. Multiparametric MRI-based radiomics nomograms provided improved prognostic ability in advanced NPC. These results provide an illustrative example of precision medicine and may affect treatment strategies. .
Yin P, Chen W, Fan Q, Yu R, Liu X, Liu T Cancer Imaging. 2025; 25(1):34.
PMID: 40082955 PMC: 11907785. DOI: 10.1186/s40644-025-00850-8.
Jin X, Li W, Guo Y, Wu G, Huang W, Chen F Eur Radiol. 2025; .
PMID: 39953153 DOI: 10.1007/s00330-025-11433-3.
Yuan H, Cheng J, Xia J, Yang Z, Xu L Discov Oncol. 2025; 16(1):35.
PMID: 39800804 PMC: 11725551. DOI: 10.1007/s12672-024-01653-2.
Tseng H, Shen C, Kao P, Chuang C, Yan D, Liao Y Cancers (Basel). 2025; 17(1.
PMID: 39796725 PMC: 11720740. DOI: 10.3390/cancers17010096.
Chen L, Wang Z, Meng Y, Zhao C, Wang X, Zhang Y Front Oncol. 2024; 14:1460426.
PMID: 39634263 PMC: 11615067. DOI: 10.3389/fonc.2024.1460426.